PATENT CLAIM ANALYSIS

Application Number: 16077417
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["424", "229100"]

Abstract:
An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.

Claim (Index 14):
The recombinant oncolytic HSV-1 according to  claim 6 , wherein the recombinant oncolytic HSV-1 comprises a first heterologous nucleic acid sequence encoding an anti-PD-1 agent and a second heterologous nucleic acid sequence encoding an anti-CTLA-4 agent.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.35135
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16068816', '16068823', '16068826', '14343108', '15489514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7879825079884394
- 35 USC 102 Novelty (BERT): 0.5480479762589331
- Combined Prediction Score: 0.7639890548154887
- Mean Citation Score: 385.645028
- Max Citation Score: 420.76712
- Similarity Product: 299.3978713790941

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test